Signs looking good in EU for Astra's Zinforo
Anglo-Swedish drugs developer AstraZeneca said its Zinforo skin infection treatment has been given a positive verdict by the Committee for Medicinal Products for Human Use (CHMP).
Anglo-Swedish drugs developer AstraZeneca said its Zinforo skin infection treatment has been given a positive verdict by the Committee for Medicinal Products for Human Use (CHMP).
The CHMP's positive opinion will now be reviewed by the European Commission, which has the authority to approve medicines for the European Union.
The CHMP reviewed data from the Phase III clinical trial programmes which included four pivotal registration trials, CANVAS 1 and 2 (relating to complicated Skin and Soft Tissue Infections, or cSSTI) and FOCUS 1 and 2 (relating to Community Acquired Pneumonia, or CAP). Clinical data demonstrated that Zinforo was effective and well tolerated in adult patients with cSSTI or CAP, including those patients with more than one underlying disorder.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
"We remain one of the few companies still committed to novel antibiotic research, with one of the world's largest antibacterial pipelines and many strong partnerships to address this significant unmet medical need," noted Martin Mackay, President of Research & Development at Astra.
Astra has been granted exclusive commercial rights and co-exclusive development rights for ceftaroline fosamil (.i.e Zinforo) by Forest Labs for all countries except the USA, Canada and Japan.
AstraZeneca has made regulatory submissions in a number of countries where it has commercialisation rights and further submissions are planned in 2012.
JH
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
-
UK-US trade deal announced: US cuts tariffs on UK car imports to 10%
Keir Starmer and Donald Trump have announced a UK-US trade deal, but the US president has refused to lift baseline tariffs on most UK goods. What does it mean for the UK?
-
How to use mid-caps to diversify from the US
Medium sized companies are overlooked by investors but could offer an attractive ‘sweet spot’. We consider the case for mid-caps amid market volatility.